Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LMNL

Liminal BioSciences (LMNL) Stock Price, News & Analysis

Liminal BioSciences logo

About Liminal BioSciences Stock (NASDAQ:LMNL)

Advanced Chart

Key Stats

Today's Range
$8.50
$8.50
50-Day Range
$8.38
$8.50
52-Week Range
$3.10
$8.50
Volume
N/A
Average Volume
63,470 shs
Market Capitalization
$26.35 million
P/E Ratio
29.31
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Receive LMNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter.

LMNL Stock News Headlines

2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
See More Headlines

LMNL Stock Analysis - Frequently Asked Questions

Liminal BioSciences Inc. (NASDAQ:LMNL) announced its quarterly earnings data on Monday, November, 15th. The company reported $27.40 EPS for the quarter, beating the consensus estimate of ($2.80) by $30.20. The firm earned $0.14 million during the quarter, compared to analysts' expectations of $0.02 million. Liminal BioSciences had a net margin of 248.35% and a negative trailing twelve-month return on equity of 88.44%.

Liminal BioSciences's stock reverse split on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Liminal BioSciences investors own include Corbus Pharmaceuticals (CRBP), Bionano Genomics (BNGO), HubSpot (HUBS), iBio (IBIO), Dynavax Technologies (DVAX), Diamondback Energy (FANG) and NIO (NIO).

Company Calendar

Last Earnings
11/15/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMNL
Employees
251
Year Founded
N/A

Profitability

Trailing P/E Ratio
29.31
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$380,000.00
Pretax Margin
-5,729.40%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Price / Cash Flow
N/A
Book Value
$8.97 per share
Price / Book
0.95

Miscellaneous

Free Float
3,036,000
Market Cap
$26.35 million
Optionable
Not Optionable
Beta
1.03
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:LMNL) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners